A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs [disease-modifying antirheumatic drugs] Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options

Trial Profile

A Phase III, Multi-Center, Open Label Study to Evaluate the Efficacy, Tolerability and Safety of Abatacept (BMS-188667) in Subjects With Active Rheumatoid Arthritis on Background Non-Biologic DMARDs [disease-modifying antirheumatic drugs] Who Have an Inadequate Response to Anti-TNF Therapy and Have Limited Therapeutic Options

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Sep 2014

At a glance

  • Drugs Abatacept; Disease-modifying antirheumatics; Tumour necrosis factor
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ARRIVE
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Sep 2009 Actual patient number changed from 391 to 535 as reported by ClinicalTrials.gov.
    • 01 Apr 2008 Number of patients enrolled updated (n=391 versus planned enrollment of 1000).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top